Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 17, 2017
Issued Date -
N/A
app pub date -
Mar 24, 2014
filing date -
Mar 25, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully